Alpha-1 Antitrypsin Drugs - Global Market Trajectory & Analytics

Global Alpha-1 Antitrypsin Drugs Market to Reach $2 Billion by 2027

Amid the COVID-19 crisis, the global market for Alpha-1 Antitrypsin Drugs estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$2 Billion by 2027, growing at a CAGR of 9.6% over the period 2020-2027.



The U.S. Market is Estimated at $319.3 Million, While China is Forecast to Grow at 9% CAGR

The Alpha-1 Antitrypsin Drugs market in the U.S. is estimated at US$319.3 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$354.1 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 43 Featured):

• Abeona Therapeutics
• Alnylam Pharmaceuticals
• Applied Genetic Technologies Corp
• Arrowhead Research Corporation
• Baxalta
• Baxter
• CSL Behring
• Grifols
• Kamada
• Shire
• Takeda Pharmaceutical Company Limited